within Pharmacolibrary.Drugs.ATC.R;

model R03AL03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0009333333333333333,
    adminDuration  = 600,
    adminMass      = 55 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.165,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.095,
    k12             = 104,
    k21             = 104
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AL03</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vilanterol and umeclidinium bromide is a fixed-dose combination of a long-acting beta2-adrenergic agonist (vilanterol) and a long-acting muscarinic antagonist (umeclidinium). It is approved and used as a maintenance treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult subjects following inhaled administration of the fixed dose combination.</p><h4>References</h4><ol><li><p>Kelleher, DL, et al., &amp; Thomas, P (2012). Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. <i>PloS one</i> 7(12) e50716–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0050716&quot;>10.1371/journal.pone.0050716</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23284643/&quot;>https://pubmed.ncbi.nlm.nih.gov/23284643</a></p></li><li><p>Mehta, R, et al., &amp; Lipson, DA (2020). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. <i>Clinical pharmacokinetics</i> 59(1) 67–79. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00794-w&quot;>10.1007/s40262-019-00794-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31321713/&quot;>https://pubmed.ncbi.nlm.nih.gov/31321713</a></p></li><li><p>Yang, S, et al., &amp; Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). <i>Clinical pharmacokinetics</i> 60(7) 887–896. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-00988-1&quot;>10.1007/s40262-021-00988-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33598874/&quot;>https://pubmed.ncbi.nlm.nih.gov/33598874</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AL03;
